Poseida Therapeutics, Inc. (PSTX)
- Previous Close
3.3450 - Open
3.3500 - Bid 3.2800 x 100
- Ask 3.2900 x 100
- Day's Range
3.1200 - 3.3500 - 52 Week Range
1.5400 - 4.2700 - Volume
322,825 - Avg. Volume
709,688 - Market Cap (intraday)
318.409M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1700 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
poseida.comRecent News: PSTX
Performance Overview: PSTX
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PSTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PSTX
Valuation Measures
Market Cap
324.22M
Enterprise Value
210.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.76
Price/Book (mrq)
3.83
Enterprise Value/Revenue
2.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-131.95%
Return on Assets (ttm)
-24.85%
Return on Equity (ttm)
-89.90%
Revenue (ttm)
82.5M
Net Income Avi to Common (ttm)
-108.86M
Diluted EPS (ttm)
-1.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
198.65M
Total Debt/Equity (mrq)
99.96%
Levered Free Cash Flow (ttm)
-20.68M
Research Analysis: PSTX
Company Insights: PSTX
PSTX does not have Company Insights